Lumos Diagnostics Holdings (ASX:LDX) Debt-to-EBITDA : -0.98 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lumos Diagnostics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.35 Mil. Lumos Diagnostics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$11.39 Mil. Lumos Diagnostics Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-13.04 Mil. Lumos Diagnostics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.98.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lumos Diagnostics Holdings's Debt-to-EBITDA or its related term are showing as below:

ASX:LDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.99 Med: -1.08 Max: -0.17
Current: -1.72

During the past 2 years, the highest Debt-to-EBITDA Ratio of Lumos Diagnostics Holdings was -0.17. The lowest was -1.99. And the median was -1.08.

ASX:LDX's Debt-to-EBITDA is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs ASX:LDX: -1.72

Lumos Diagnostics Holdings Debt-to-EBITDA Historical Data

The historical data trend for Lumos Diagnostics Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Debt-to-EBITDA Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

Debt-to-EBITDA

-0.17

-1.99

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.42	-0.10	-0.55	-8.33	-0.98

Competitive Comparison of Lumos Diagnostics Holdings's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Lumos Diagnostics Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumos Diagnostics Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Debt-to-EBITDA falls into.

Lumos Diagnostics Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lumos Diagnostics Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3.037	+	11.543)	/	-7.344
	=	-1.99

Lumos Diagnostics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.354	+	11.386)	/	-13.036
	=	-0.98

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Lumos Diagnostics Holdings (ASX:LDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Lumos Diagnostics Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines